We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers.
- Authors
EMI GOTO; TOSHIFUMI YAMAGUCHI; NOBUHIRO HATTORI; MASAHIRO GOTO; MASAMI NISHIHARA; KAZUHISA UCHIYAMA; YOSHIYUKI RIKITAKE
- Abstract
Background/Aim: To prevent infusion-related reactions (IRRs), H1-antihistamines (H1AT) are recommended as a premedication for monoclonal antibodies, such as Ramucirumab (RAM), even though there are H1AT-related side effects, such as drowsiness and dizziness. Here, we investigated the safety of H1AT-free RAM regimens in patients with solid cancer. Patients and Methods: We retrospectively reviewed the patients with solid cancer receiving RAM without H1AT at Osaka Medical College Hospital between 2015 and 2019. Results: Among the 123 registered patients, 58 were identified as eligible. The total number of RAM infusions was 291, and the median number of RAM administration was 4 cycles (range=1-23 cycles). IRRs were not observed in any patient. Conclusion: Although our data are preliminary and limited, H1AT-free RAM regimens may be a treatment option for cancer patients having a significant risk of developing H1AT-related side effects. Further studies are needed to confirm the safety of H1AT-free RAM regimens.
- Subjects
THERAPEUTIC use of monoclonal antibodies; ANTIHISTAMINES; CANCER treatment; PREMEDICATION; DRUG efficacy; DRUG side effects
- Publication
In Vivo, 2020, Vol 34, Issue 6, p3489
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12189